Editorial: Virus-like particles show promise as candidates for new vaccine strategies

Future Virology

Volumn 5, Issue 4, 2010, Pages 371-374

  Federico, Maurizio ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT ANTIGEN; VACCINE; VIRUS ENVELOPE PROTEIN;

BACTERIOPHAGE; EDITORIAL; HEPATITIS B; HEPATITIS B VIRUS; HEPATITIS C VIRUS; HUMAN; IMMUNIZATION; LENTIVIRINAE; NANOBIOTECHNOLOGY; NONHUMAN; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION; RETROVIRUS; VIRION; VIRUS INFECTION; VIRUS LIKE AGENT; WART VIRUS;

EID: 77954939132     PISSN: 17460794     EISSN: None     Source Type: Journal    
DOI: 10.2217/fvl.10.29     Document Type: Editorial

References (49)

1. Grgacic EV, Anderson DA: Virus-like particles: passport to immune recognition. Methods 40(1), 60-65 (2006).
2. Da Silva DM, Schiller JT, Kast WM: Heterologous boosting increases immunogenicity of chimeric papillomavirus virus-like particle vaccines. Vaccine 21(23), 3219-3227 (2003).
3. Schiller JT, Lowy DR: Papillomavirus-like particle vaccines. J. Natl Cancer Inst. Monogr. 28, 50-54 (2001).
4. Newman M, Suk FM, Cajimat M, Chua PK, Shih C: Stability and morphology comparisons of self-assembled virus-like particles from wild-type and mutant human hepatitis B virus capsid proteins. J. Virol. 77(24), 12950-12960 (2003).
5. Zhao W, Liao GY, Jiang YJ, Jiang SD: Expression and self-assembly of HCV structural proteins into virus-like particles and their immunogenicity. Chin. Med. J. (Engl.) 117(8), 1217-1222 (2004).
6. Johnson MC, Scobie HM, Ma YM, Vogt VM: Nucleic acid-independent retrovirus assembly can be driven by dimerization. J. Virol. 76(22), 11177-11185 (2002).
7. Young KR, Ross TM: Particle-based vaccines for HIV-1 infection. Curr. Drug Targets Infect. Disord. 3(2), 151-169 (2003).
8. Costa-Rivero N, Aguilar JC, Musacchio A et al.: Characterization of the HCV core virus-like particles produced in the methylotrophic yeast Pichia pastoris. Biochem. Biophys. Res. Commun. 287(1), 122-125 (2001).
9. Woo MK, An JM, Kim JD, Park SN, Kim HJ: Expression and purification of human papillomavirus 18 L1 virus-like particle from Saccharomyces cerevisiae. Arch. Pharm. Res. 31(2), 205-209 (2008).
10. Lu MW, Liu W, Lin CS: Infection competition against grouper nervous necrosis virus by virus-like particles produced in Escherichia coli. J. Gen. Virol. 84(Pt 6), 1577-1582 (2003).
11. Bertolotti-Ciarlet A, Ciarlet M, Crawford SE, Conner ME, Estes MK: Immunogenicity and protective efficacy of rotavirus 2/6-virus-like particles produced by a dual baculovirus expression vector and administered intramuscularly, intranasally, or orally to mice. Vaccine 21(25-26), 3885-3900 (2003).
12. Buonaguro L, Tornesello ML, Tagliamonte M etal.: Baculovirus-derived human immunodeficiency virus type 1 virus-like particles activate dendritic cells and induce ex vivo T-cell responses. J. Virol. 80(18), 9134-9143 (2006).
13. Huang Z, Elkin G, Maloney BJ et al.: Virus-like particle expression and assembly in plants: hepatitis B and Norwalk viruses. Vaccine 23(15), 1851-1858 (2005).
14. Malboeuf CM, Simon DA, Lee YE et al.: Human papillomavirus-like particles mediate functional delivery of plasmid DNA to antigen presenting cells in vivo. Vaccine 25(17), 3270-3276 (2007).
15. Wu M, Sherwin T, Brown WL, Stockley PG: Delivery of antisense oligonucleotides to leukemia cells by RNA bacteriophage capsids. Nanomedicine 1(1), 67-76 (2005).
16. Wang Q, Lin T, Tang L, Johnson JE, Finn MG: Icosahedral virus particles as addressable nanoscale building blocks. Angew. Chem. Int. Ed. Engl. 41(3), 459-462 (2002).
17. Ramqvist T, Andreasson K, Dalianis T: Vaccination, immune and gene therapy based on virus-like particles against viral infections and cancer. Expert Opin. Biol. Ther. 7(7), 997-1007 (2007).
18. McAleer WJ, Buynak EB, Maigetter RZ et al.: Human hepatitis B vaccine from recombinant yeast. Nature 307, 178-180 (1984).
19. Garland SM, Hernandez-Avila M, Wheeler CM et al. : Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N. Engl. J. Med. 356(19), 1928-1943 (2007). (Pubitemid 46740303)
20. Deml L, Speth C, Dierich MP, Wolf H, Wagner R: Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol. Immunol. 42(2), 259-277 (2005).
21. Bellier B, Dalba C, Clerc B et al.: DNA vaccines encoding retrovirus-based virus-like particles induce efficient immune responses without adjuvant. Vaccine 24(14), 2643-2655 (2006).
22. Rueda P, Martinez-Torrecuadrada JL, Sarraseca J et al.: Engineering parvovirus-like particles for the induction of B-cell, CD4+ and CTL responses. Vaccine 18(3-4), 325-332 (1999).
23. Schmidt U, Rudolph R, Bohm G: Binding of external ligands onto an engineered virus capsid. Protein Eng. 14(10), 769-774 (2001).
24. Inoue T, Kawano MA, Takahashi RU et al.: Engineering of SV40-based nano-capsules for delivery of heterologous proteins as fusions with the minor capsid proteins VP2/3. J. Biotechnol. 134(1-2), 181-192 (2008).
25. Muller M, Zhou J, Reed TD et al.: Chimeric papillomavirus-like particles. Virology 234(1), 93-111 (1997).
26. Greenstone HL, Nieland JD, de Visser KE et al.: Chimeric papillomavirus virus-like particles elicit antitumor immunity against the E7 oncoprotein in an HPV16 tumor model. Proc. Natl Acad. Sci. USA 95(4), 1800-1805 (1998).
27. Paliard X, Liu Y, Wagner R et al.: Priming of strong, broad, and long-lived HIV type 1 p55gag-specific CD8+ cytotoxic T cells after administration of a virus-like particle vaccine in rhesus macaques. AIDS Res. Hum. Retroviruses 16(3), 273-282 (2000).
28. Wagner R, Deml L, Fliessbach H, Wanner G, Wolf H: Assembly and extracellular release of chimeric HIV-1 Pr55gag retrovirus-like particles. Virology 200(1), 162-175 (1994).
29. Young KR, Ross TM: Elicitation of immunity to HIV type 1 Gag is determined by Gag structure. AIDS Res. Hum. Retroviruses 22(1), 99-108 (2006).
30. Luo L, Li Y, Ha SD, Kang CY: Hydrophilicity dependent budding and secretion of chimeric HIV Gag-V3 virus-like particles. Virus Genes 35(2), 187-193 (2007).
31. Kattenbeck B, von PA, Rohrhofer A, Wolf H, Modrow S: Inhibition of human immunodeficiency virus type 1 particle formation by alterations of defined amino acids within the C terminus of the capsid protein. J. Gen. Virol. 78(Pt 10) 2489-2496 (1997).
32. Muller B, Daecke J, Fackler OT et al.: Construction and characterization of a fluorescently labeled infectious human immunodeficiency virus type 1 derivative. J. Virol. 78(19), 10803-10813 (2004).
33. Buonaguro L, Visciano ML, Tornesello ML et al. : Induction of systemic and mucosal cross-clade neutralizing antibodies in BALB/c mice immunized with human immunodeficiency virus type 1 clade A virus-like particles administered by different routes of inoculation. J. Virol. 79(11), 7059-7067 (2005).
34. Klasse PJ, Sattentau QJ: Occupancy and mechanism in antibody-mediated neutralization of animal viruses. J. Gen. Virol. 83(Pt 9), 2091-2108 (2002).
35. Reading SA, Dimmock NJ: Neutralization of animal virus infectivity by antibody. Arch. Virol. 152(6), 1047-1059 (2007).
36. Anderson RJ, Schneider J: Plasmid DNA and viral vector-based vaccines for the treatment of cancer. Vaccine 25(Suppl. 2), B24-B34 (2007).
37. Wang Z, La RC, Lacey SF et al.: Attenuated poxvirus expressing three immunodominant CMV antigens as a vaccine strategy for CMV infection.J. Clin. Virol. 35(3), 324-331 (2006).
38. Gilbert PA, McFadden G: Poxvirus cancer therapy. Recent Pat. Antiinfect. Drug Discov. 1(3), 309-321 (2006).
39. He Y, Munn D, Falo LD Jr: Recombinant lentivector as a genetic immunization vehicle for antitumor immunity. Expert Rev. Vaccines 6(6), 913-924 (2007).
40. Liniger M, Zuniga A, Naim HY: Use of viral vectors for the development of vaccines. Expert Rev. Vaccines 6(2), 255-266 (2007).
41. Yang TC, Millar JB, Grinshtein N et al.: T-cell immunity generated by recombinant adenovirus vaccines. Expert Rev. Vaccines 6(3), 347-356 (2007).
42. Laddy DJ, Weiner DB: From plasmids to protection: a review of DNA vaccines against infectious diseases. Int. Rev. Immunol. 25(3-4), 99-123 (2006).
43. Liu MA, Ulmer JB: Human clinical trials of plasmid DNA vaccines. Adv. Genet. 55, 25-40 (2005).
44. Lowe DB, Shearer MH, Kennedy RC: DNA vaccines: successes and limitations in cancer and infectious disease. J. Cell Biochem. 98(2), 235-242 (2006).
45. Peretti S, Schiavoni I, Pugliese K, Federico M: Cell death induced by the herpes simplex virus-1 thymidine kinase delivered by human immunodeficiency virus-1-based virus-like particles. Mol. Ther. 12(6), 1185-1196 (2005).
46. Marsac D, Loirat D, Petit C, Schwartz O, Michel ML: Enhanced presentation of major histocompatibility complex class I-restricted human immunodeficiency virus type 1 (HIV-1) Gag-specific epitopes after DNA immunization with vectors coding for vesicular stomatitis virus glycoprotein- pseudotyped HIV-1 Gag particles. J. Virol. 76(15), 7544-7553 (2002).
47. Di Bonito P, Grasso F, Mochi S et al.: Anti-tumor CD8+ T cell immunity elicited by HIV-1-based virus-like particles incorporating HPV-16 E7 protein. Virology 395(1), 45-55 (2009).
48. Federico M: From lentiviruses to lentivirus vectors. Methods Mol. Biol. 229, 3-15 (2003).
49. Segura MM, Garnier A, Durocher Y, Ansorge S, Kamen A: New protocol for lentiviral vector mass production. Methods Mol. Biol. 614, 39-52 (2010).